Do Institutional Investors Hate Insys Therapeutics Inc (NASDAQ:INSY)?

April 17, 2018 - By Marguerite Chambers

Sentiment for Insys Therapeutics Inc (NASDAQ:INSY)

Insys Therapeutics Inc (NASDAQ:INSY) institutional sentiment decreased to 0.76 in 2017 Q4. Its down -0.49, from 1.25 in 2017Q3. The ratio has worsened, as 38 hedge funds increased and opened new holdings, while 50 cut down and sold equity positions in Insys Therapeutics Inc. The hedge funds in our partner’s database reported: 16.43 million shares, down from 18.21 million shares in 2017Q3. Also, the number of hedge funds holding Insys Therapeutics Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 21 Reduced: 29 Increased: 18 New Position: 20.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $499.75 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

The stock increased 8.05% or $0.51 during the last trading session, reaching $6.78. About 822,309 shares traded or 7.21% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 45.03% since April 17, 2017 and is downtrending. It has underperformed by 56.58% the S&P500.

Orbimed Advisors Llc holds 0.66% of its portfolio in INSYS Therapeutics, Inc. for 5.41 million shares. Mirae Asset Global Investments Co. Ltd. owns 1.47 million shares or 0.19% of their US portfolio. Moreover, Gsa Capital Partners Llp has 0.04% invested in the company for 67,200 shares. The California-based Eqis Capital Management Inc. has invested 0.03% in the stock. Tci Wealth Advisors Inc., a Arizona-based fund reported 7,766 shares.#img1#

INSYS Therapeutics, Inc. (NASDAQ:INSY) Ratings Coverage

Ratings analysis reveals 67% of Insys Therapeutics’s analysts are positive. Out of 3 Wall Street analysts rating Insys Therapeutics, 2 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8.0 while the high is $14.0. The stock’s average target of $9.50 is 40.12% above today’s ($6.78) share price. INSY was included in 4 notes of analysts from October 18, 2017. The firm has “Underweight” rating given on Friday, March 9 by PiperJaffray. Jefferies maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) on Wednesday, October 18 with “Buy” rating. The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) earned “Buy” rating by RBC Capital Markets on Friday, October 27. The stock has “Buy” rating by Jefferies on Friday, November 3.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: